Accretion Pharmaceuticals shareholders and shareholding pattern
NSE: ACCPLPharmaceuticals & Biotechnology
Last close ₹182.10down ₹7.20 (3.80%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹189.30.
52-week range of traded prices to 23 Oct 2026
₹54.60Low, 27 Oct 2025₹220.00High, 30 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹202 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 8 May 2026
- 20.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 8 May 2026
- 3.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 8 May 2026
- 27.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 8 May 2026
- 0.23
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,200100.0% delivered
Who owns Accretion Pharmaceuticals, filing by filing
Per cent of the company's shares. Every filing on record, from Jun 2025; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters73.52%
- Foreign institutions0.17%
- Indian institutions3.65%
- Individuals and others22.66%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Jun 2025Filed 9 Jul | Sep 2025Filed 21 Oct | Dec 2025Filed 10 Jan | Mar 2026Filed 21 Apr | Jun 2026Filed 16 Jul | Sep 2026Filed 17 Oct |
|---|---|---|---|---|---|---|
| 73.50% | 73.52% | 73.52% | 73.52% | 73.52% | 73.52% | |
| Indian promoters | 73.50% | 73.52% | 73.52% | 73.52% | 73.52% | 73.52% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 26.50% | 26.48% | 26.48% | 26.48% | 26.48% | 26.48% |
| Shares in issue | 1,11,16,000 | 1,11,16,000 | 1,11,16,000 | 1,11,16,000 | 1,11,16,000 | 1,11,16,000 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 82,75,600 | 81,70,000 | 81,70,000 | 81,70,000 | 22,23,200 | 22,23,200 |
| Promoters' shares locked in | 81,70,000 | 81,70,000 | 81,70,000 | 81,70,000 | 22,23,200 | 22,23,200 |
A dash is a line the filing did not state.
Accretion Pharmaceuticals promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Vivek Ashok Kumar Patel, 17.69%. The filing names 46 more members with no shares.
| Holder | |||
|---|---|---|---|
| Vivek Ashok Kumar PatelIndividuals and Hindu undivided families | 17.69% | 19,66,500 | 28.26% |
| Hardik Mukundbhai PrajapatiIndividuals and Hindu undivided families | 17.69% | 19,66,500 | 28.26% |
| Harshad Nanubhai RathodIndividuals and Hindu undivided families | 17.69% | 19,66,500 | 28.26% |
| Mayur Popatlal SojitraIndividuals and Hindu undivided families | 17.69% | 19,66,500 | 28.26% |
| Shweta SojitraIndividuals and Hindu undivided families | 0.68% | 76,000 | 0.00% |
| Vaishaki Hardik PrajapatiIndividuals and Hindu undivided families | 0.68% | 76,000 | 0.00% |
| Ankita Vivek PatelIndividuals and Hindu undivided families | 0.68% | 76,000 | 0.00% |
| Pooja Harshad RathodIndividuals and Hindu undivided families | 0.68% | 76,000 | 0.00% |
| Rekhaben Karshandas GhetiyaIndividuals and Hindu undivided families | 0.02% | 2,400 | 0.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Accretion Pharmaceuticals, filing by filing
Per cent, on the same shares as the split above.
| Holder | Dec 2025Filed 10 Jan | Mar 2026Filed 21 Apr | Jun 2026Filed 16 Jul | Sep 2026Filed 17 Oct |
|---|---|---|---|---|
| UNICORN FUNDAlternative investment funds | – | – | 2.76% | 3.65% |
| RAJINDRA VALSALANResident individuals, over ₹2 lakh at face value | 1.13% | 1.04% | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.